2019
Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer
Gupta S, Neumeister V, McGuire J, Song YS, Acs B, Ho K, Weidler J, Wong W, Rhees B, Bates M, Rimm DL, Bossuyt V. Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer. Npj Breast Cancer 2019, 5: 28. PMID: 31482108, PMCID: PMC6715641, DOI: 10.1038/s41523-019-0122-x.Peer-Reviewed Original ResearchBreast cancerQuantitative immunofluorescenceIHC 0/1Systemic treatmentRT-qPCRClinical Oncology/CollegeAdditional outcome informationProtein expressionReal-time quantitative reverse transcription polymerase chain reactionHER2 protein levelsQuantitative reverse transcription polymerase chain reactionReverse transcription-polymerase chain reactionTranscription-polymerase chain reactionASCO/CAP recommendationsRNA/protein expressionQIF scoresPatient characteristicsClinical outcomesTrastuzumab treatmentSurvival outcomesPolymerase chain reactionIHC 2Treatment decisionsCAP recommendationsPatients
2018
Nuclear shape and orientation features from H&E images predict survival in early-stage estrogen receptor-positive breast cancers
Lu C, Romo-Bucheli D, Wang X, Janowczyk A, Ganesan S, Gilmore H, Rimm D, Madabhushi A. Nuclear shape and orientation features from H&E images predict survival in early-stage estrogen receptor-positive breast cancers. Laboratory Investigation 2018, 98: 1438-1448. PMID: 29959421, PMCID: PMC6214731, DOI: 10.1038/s41374-018-0095-7.Peer-Reviewed Original ResearchConceptsEarly-stage estrogen receptor-positive breast cancerEstrogen receptor-positive breast cancerReceptor-positive breast cancerBreast cancerRank sum testHazard ratioHistomorphometric featuresShort-term overall survivalLymph node negativeTissue microarray cohortPoor survival outcomesUnivariate survival analysisWilcoxon rank sum testAdjuvant chemotherapyMicroarray cohortOverall survivalNode negativeT stageHistology gradePatient survivalSurvival outcomesPathological parametersNuclear gradeOutcome groupPoor survival
2009
Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis
Rothberg BE, Bracken MB, Rimm DL. Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis. Journal Of The National Cancer Institute 2009, 101: 452-474. PMID: 19318635, PMCID: PMC2720709, DOI: 10.1093/jnci/djp038.Peer-Reviewed Original ResearchConceptsCohort studyCutaneous melanomaMelanoma cell adhesion moleculeSystematic reviewEarly-stage cutaneous melanomaPotential prognostic valueMatrix metalloproteinase-2Cell nuclear antigenREMARK criteriaAdjuvant therapyMultivariable analysisREMARK guidelinesRisk stratificationPrognostic valueSurvival outcomesIncomplete adherenceMelanoma outcomesClinical managementImmunohistochemical expressionCell adhesion moleculeInclusion criteriaKi-67Tissue biomarkersClinical practiceMetalloproteinase-2